Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

mab may represent a valuable new approach to treating cancer," said Dr. Raghunadharao Digumarti, professor of medical oncology at the Nizams Institute of Medical Sciences and a Phase II bavituximab cancer trial investigator who presented the data at ASCO on behalf of the study team. "We are pleased with the response rates and progression free survival data seen in the initial group of breast cancer patients and look forward to reporting additional results from the entire Phase II breast cancer study later this year."

The primary objective of this multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. In the trial's two-stage design, 15 patients with advanced breast cancer were enrolled in the first cohort. The 71% objective tumor response rate seen in the 14 evaluable patients in the first cohort compares favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and it exceeded the pre-specified primary endpoint needed to expand the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall. With patient enrollment complete, dosing and follow-up are continuing. The safety profile of bavituximab plus docetaxel in the study has been acceptable, with minor infusion reactions, epistaxis and nasal dryness among the most common reported bavituximab-related side effects. These did not require dose modification or treatment discontinuation.

Separately, Peregrine reported that researchers will present data at ASCO today from a Phase I study assessing the safety and pharmacokinetic (PK) properties of bavituximab as monotherapy in patients with advanced refractory cancers. This multi-center open label safety study is currently enrolling patients in the final cohort according to the initial study design. The study authors report on their experience with the first 25 patients in the st
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 ... sponsoring of the winners of the 2015 BeHEARD science ... Institute that offers rare disease researchers, access to the ... will use its drug repositioning and pathway analytics capability ... at Wylder Nation Foundation in the study of Niemann-Pick ...
(Date:9/2/2015)... Sept. 2, 2015 Australian prostate cancer technology ... Australian science prize recognising ,outstanding, science that uses its ... globally launch a novel prostate cancer diagnostic test known ... level consortium taking out the peer-reviewed Australian Museum Eureka ... This prize is awarded for ground ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... miRNA research is now one of the most ... Genetic Engineering and Biotechnology News (GEN). Scientists around ... or underexpression of specific miRNAs on the development ... diseases, according to an article titled miRNA-Regulated Pathways ...
... LAKE CITY, Feb. 29 DW Healthcare ... announced today the sale of one,of its ... Laboratory,Corporation of America(R) Holdings (LabCorp(R)), one of ... Salt Lake City, UT, Tandem,Labs is a ...
... 29 Micromet, Inc.,(Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune,diseases, today announced that ... Micromet, will present at the Susquehanna Financial,Group,s SIGnificant ... 10:30 am ET at the W Hotel in ...
Cached Biology Technology:Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008 2
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... novel vaccine study from South Dakota State University (SDSU) will ... American Association of Pharmaceutical Scientists, (AAPS) National Biotechnology Conference (NBC). ... 22 at the Sheraton San Diego Hotel and Marina. ... the immune system to fight against a pathogen that causes ...
... A novel study reports that white men and women of ... valgus) and lesser toe deformities, including hammer or claw toe. ... heritability of foot disorders in humansappear in Arthritis Care ... of the American College of Rheumatology (ACR). Previous ...
... The AGA Research Foundation is honored to announce the ... Digestive Cancer, which will support Andrew D. Rhim, MD, ... of Pennsylvania, Philadelphia, as he furthers his research on ... cancer progression. "The AGA Research Foundation is humbled ...
Cached Biology News:Germ-fighting vaccine system makes great strides in delivery 2Blame your parents for bunion woes 2AGA Research Foundation grant furthers digestive cancer research 2
Assay Diluent, 10 L...
... Clone/PAD: ZMD.474. Immunogen: Synthetic peptide ... the mouse junctophilin-3. Specificity: Specific ... junctophilin-3 protein. Reactivity: Mouse (positive ... hippocampus and heart tissues). Applications: ...
...
... Cloning Kit, 40 reactions. Optimized for ... all PCR products with blunt or ... by offering consistently better signal-to-noise ratios ... positive clones.Amplicons generated by proof-reading thermostable ...
Biology Products: